Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%

Autolus Therapeutics plc (NASDAQ:AUTL) shares traded down 5.2% on Tuesday . The company traded as low as $4.02 and last traded at $4.03. 125,432 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,557,722 shares. The stock had previously closed at $4.25.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Truist Financial upped their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Stock Down 8.2 %

The firm has a fifty day moving average of $4.09 and a 200-day moving average of $4.94. The firm has a market cap of $1.04 billion, a P/E ratio of -3.25 and a beta of 2.11.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million during the quarter, compared to analyst estimates of $50.00 million. During the same quarter last year, the company posted ($0.23) EPS. Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics in the 1st quarter valued at approximately $100,000. B. Riley Wealth Advisors Inc. bought a new position in Autolus Therapeutics in the first quarter valued at approximately $108,000. SG Americas Securities LLC bought a new position in Autolus Therapeutics in the first quarter valued at approximately $127,000. EntryPoint Capital LLC boosted its stake in shares of Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after acquiring an additional 11,456 shares during the period. Finally, EWA LLC boosted its stake in shares of Autolus Therapeutics by 40.2% during the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock worth $155,000 after acquiring an additional 7,361 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.